EORTC CLTF Meeting
St. Gallen 2018
27 – 29 September 2018
St. Gallen, Switzerland

Final Programme

Information
Kantonsspital St. Gallen
Silke Knoll
Klinik für Dermatologie, Venerologie und Allergologie
Roschacher Strasse 95
CH-9007 St. Gallen/Switzerland
silke.knoll@kssg.ch
www.kssg.ch
Dear colleagues,

Welcome to the 2018 EORTC CLTF meeting!

The focus of this conference will be on biology, treatment, and patient view in Cutaneous Lymphoma. We look forward to a series of presentations by world renowned experts and young researchers.

Our guest speakers will provide valuable insights into their fields of expertise: Professor Irving Weissman, Stanford University, will give his lecture on normal and neoplastic stem cells, tumor progression and programmed cell removal. The focus of the lecture by Professor Rachael Clark, Harvard Medical School, will be on patient-driven insights into the biology of cutaneous T cell lymphoma. On Saturday morning, Professor Günter Burg and Professor Helmut Kerl will review the early days of our task force and the beginnings of the modern understanding of cutaneous lymphoma.

We feel very privileged that Elsevier has agreed to publish an abstract book in the European Journal of Cancer – a novum for our task force. More than 100 accepted abstracts underline the continuous scientific development and the importance of our annual EORTC CLTF meeting.

Let’s foster scientific and social interactions among colleagues and friends in a beautiful environment – welcome to St. Gallen!

Antonio Cozzio
St.Gallen Chair

Julia Scarisbrick
EORTC CLTF Chair

Emmanuella Guenova
St.Gallen Committee

Werner Kempf
St.Gallen Committee

Felicitas Hitz
St.Gallen Committee
**Congress secretariat**
Kantonsspital St.Gallen
Silke Knoll
Klinik für Dermatologie, Venerologie und Allergologie
CH–9007 St.Gallen
phone + 41 71 494 20 30
silke.knoll@kssg.ch
During the conference onsite and by phone:
+ 41 71 494 20 30

**Venue**
Olma Messen St.Gallen Halle 9.2
St. Jakobstrasse 94
CH–9008 St.Gallen
www.olma-messen.ch

**Hotel accommodation and touristic information**
St.Gallen Bodensee Tourismus
Bankgasse 9
CH–9001 St.Gallen
phone +41 71 227 37 37
www.st.gallen-bodensee.ch
During the conference onsite

**Opening hours conference venue**
Thursday, 27 September 2018 08.00 – 20.30
Friday, 28 September 2018 07.00 – 19.30
Saturday 29 September 2018 07.30 – 16.00

**Comdities**

**Conference chairmen**
Antonio Cozzio, Switzerland, Congress president
Julia Scarisbrick, UK
Emmanuella Guenova, Switzerland
Werner Kempf, Switzerland
Felicitas Hitz, Switzerland

**Scientific committee**
Chalid Assaf, Germany
Martine Bagot, France
Helmut Beltraminelli, Switzerland
Emilio Berti, Italy
Marie Beylot-Barry, France
Edgar Dippel, Germany
Reinhard Dummer, Switzerland
Emmilia Hodak, Israel
Claus-Detlev Klemke, Germany
Robert Knobler, Austria
Pablo Ortiz, Spain
Pietro Quaglino, Italy
Ramon Pujol, Spain
Evangelina Papadavid, Greece
Annamari Ranki, Finland
Rudolf Stadler, Germany
Franz Trautinger, Austria
Maarten Vermeer, Netherlands
Sean Whittaker, UK
Rein Willemze, Netherlands

**Patronage by professional societies**

www.eortc.org
www.kssg.ch
Thursday, 27 September 2018

07.45 – 09.00 EORTC/ISCL/USCLC Chairs Meeting: clinical endpoints revision (closed meeting) Hotel Einstein

09.00 – 10.20 EORTC Board meeting (closed meeting) Hotel Einstein

10.45 – 12.00 PROCLIPI meeting OLMA Messen Hall 9.2

09.30 – 12.30 Registration OLMA Messen Hall 9.2

12.30 Congress Opening Antonio Cozzio, Switzerland Julia Scarisbrick, UK

12.45 – 13.45 Lunch Symposium (sponsored content)

13.45 – 15.15 Session 1: Biologic Insights I 
Molecular markers and targets
Chairs: Chalid Assaf, Germany Claus-Detlev Klemke, Germany Sean Whittaker, UK

• Tumor clone frequency is a robust predictor of progression and survival in patients with Stage IB mycosis fungoides (Adele De Masson) abstract number 001
• KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia (ATLL) (Maxime Battistella) abstract number 020
• Identification of predictive markers for stage progression in primary cutaneous anaplastic large cell lymphoma (Jin Ah Yoo) abstract number 021
• Standardized flow cytometry (EuroFlow) demonstrates heterogeneous T-cell origin of Sézary lymphoma cells (Safa Najidh) abstract number 022
• Prognostic miRNA classifier in early-stage mycosis fungoides: Development and validation in a Danish nationwide study (Lise M. Lindahl) abstract number 027

15.15 – 15.45 Coffee/Tea break, poster and industrial exhibition

15.45 – 16.30 Session 2: PROCLIPI analysis
Chairs: Antonio Cozzio, Switzerland Franz Trautinger, Austria

• The PROCLIPI Study; A prototype registry for rare disease with global collaboration for establishment of a prognostic index in mycosis fungoides and Sézary syndrome (Julia Scarisbrick) abstract number 015
• Treatment of early-stage Mycosis fungoides: results from the PROCLIPI Study (Pietro Quaglino) abstract number 092
• Updates from the Central Pathology Review in Patients with Advanced Stage Mycosis Fungoides (MF) and Sézary Syndrome (SS) for the Global PROCLIPI Study (Alejandro Gru) abstract number 044
• Lymph Node Imaging in patch/plaque mycosis fungoides; enlarged LN are infrequent but lymphomatous nodal involvement may occur and upstage patients to advanced disease (Emmilia Hodak) abstract number 070

• The tumour phenotype of mycosis fungoides clusters into three heterogeneous surface expression profiles (Duncan Murray) abstract number 032
• Dysregulation of the expression of antimicrobial peptides in patients with cutaneous T-cell lymphoma (Ulrike Wehkamp) abstract number 042
• Differences in the miRNA expression profiles of erythrodermic mycosis fungoides and Sézary syndrome (Anne Hald Rittig) abstract number 008
• Revisiting blood classification in Mycosis Fungoides and Sézary syndrome with the KIR3DL2 marker (Helene Moins-Teisserenc) abstract number 028
16.30 – 17.15  Guest Lecture: Normal and neoplastic stem cells: tumor progression and programmed cell removal
   Prof. Irving L. Weissman, Stanford University, USA

17.15 – 18.15  Young investigator poster walk
   Emmanuella Guenova, Switzerland
   Lise Lindahl, Denmark
   Vieri Grande, Italy
   Alessandro Pileri, Italy
   Malgorzata Bobrowicz, Poland

18.30 – 20.00  Welcome reception, networking

08.00 – 09.00  Breakfast Symposium
   (sponsored content)

09.00 – 10.30  Session 3: Biologic Insights II – Genomics and molecular biology
   Chairs: Maarten Vermeer, Netherlands
          Robert Knobler, Austria
          Reinhard Dummer, Switzerland

   • Resminostat affects transcriptional regulation of disease-related processes in CTCL
     (Matthias Borgmann) abstract number 003

   • The bioactive content of CTCL cell line-derived exosomes and small microvesicles: First study in CTCL
     (Lilach Moyal) abstract number 010

   • Genomic analysis reveals recurrent deletion of HNRNPK and SOCS1 in mycosis fungoides
     (Armando Bastidas Torres) abstract number 019

   • 1p36 deletion is associated with TNFRSF14 mutations in primary cutaneous follicle center lymphoma
     (Bence Bátai) abstract number 029

   • Functional interrogation of STAT5 variants in Primary Cutaneous T-cell Lymphoma (CTCL)
     (Rosie Butler) abstract number 033

   • Methylation analysis in Sézary syndrome and integration of exome and transcriptome data
     (Raquel Rabionet) abstract number 036

   • Mutations in highly conserved phosphatase PP5 identified in CTCL lead to dysregulation of the MAPK pathway
     (Charlotte Flanagan) abstract number 038

   • Genomic alterations using OncoScan in adult T-cell leukemia/lymphoma: a characterization of 69 cases from Peru, the United States, Brazil, and Spain
     (Jonathan Davick) abstract number 041
10.30 – 11.00  Coffee/Tea break, poster and industrial exhibition

11.00 – 12.30  Session 4: Quality of Life
Chairs: Antonio Cozzio, Switzerland
Pablo Ortiz, Spain
Julia Scarisbrick, UK

• The impact of skin infection on quality of life in patients with mycosis fungoides and Sézary syndrome (Chenjing Peng) abstract number 103
• Managing HRQL in patients with CTCL: physician responses from the 2018 USCLC Workshop (John Zic) abstract number 104
• Quality of life in patients with mycosis fungoides and Sézary syndrome is significantly worse in female patients, Sézary syndrome and those with more extensive skin involvement (Kevin Molloy) abstract number 106
• Quality of life in cutaneous T cell lymphoma patients treated with the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from MAVORIC (Pierluigi Porcu) abstract number 105
• Health-related quality of life in cutaneous lymphomas: a state-of-the-art review (Constanze Jonak) abstract number 107
• The Lymphoma Coalition global patient survey (Susan Thornton , CEO Cutaneous Lymphoma Foundation, 15 min.)
• Panel discussion

12.45 – 13.45  Lunch Symposium (sponsored content)

13.45 – 14.15  Session 5: Biologic Insights III: Translational research
Chairs: Emmanuella Guenova, Switzerland
Felicitas Hitz, Switzerland
Emmila Hodak, Israel

• Establishment of an in vivo model of patient-derived SS for therapy validation (Lluis Espinosa) abstract number 035

14.15 – 15.00  Guest Lecture: Patient driven insights into the biology of cutaneous T cell lymphoma
Prof. Rachael Clark, Brigham and Women’s Hospital, Harvard Medical School, USA

15.00 – 15.30  Coffee/Tea break, poster and industrial exhibition

15.30 – 16.40  Session 6: Histopathology
Chairs: Helmut Beltraminelli, Switzerland
Emilio Berti, Italy
Werner Kempf, Switzerland

• Understanding the tumor microenvironment in the primary cutaneous CD30-positive lymphoproliferative disorders (Cristiane Ferreira) abstract number 002
• The role of immune-checkpoints in mycosis fungoides (Alessandro Pileri) abstract number 004
• Dermal CD8+ lymphoproliferations – results of the EORTC CLTF task force histopathology group workshop Zurich 2017 (Werner Kempf, 15 min.)
• The regulation of PD-L1 expression by miRNAs in cutaneous T-cell lymphoma (Christiane Querfeld) abstract number 024
• Indolent cytotoxic cutaneous lymphomas with clinical and histological features of atypical lymphoid proliferation not otherwise specified (Silvia Alberti-Violetti) abstract number 061
16.40 – 17.10 Coffee/Tea break, poster and industrial exhibition

17.10 – 18.10 Session 7: Treatment and clinical aspects
Chairs: Martine Bagot, France
Edgar Dippel, Germany
Ramon Pujol, Spain
- A novel approach to low dose Total skin electron beam therapy (TSEBT)
  (Taqdees Suhail) abstract number 085
- Hydroa vacciniforme and hydroa vacciniforme-like lymphoproliferative disorder: Disease spectrum, responsible T-cell subsets and prognosis
  (Keiji Iwatsuki) abstract number 108
- 18F-FDG-PET/CT for staging Mycosis Fungoïdes and Sézary Syndrome
  (Vieri Grandi) abstract number 094
- Granulomatous slack skin: a series of cases
  (Jade Cury Martins) abstract number 069
- Intralesional Injection of the CD47-blocking Immune Checkpoint Inhibitor TTI-621 (SIRPaFc) Induces Antitumor Activity Patients with Relapsed/Refractory Mycosis Fungoïdes and Sézary Syndrome: Interim Results of a Multicenter Phase 1 Trial
  (Christiane Querfeld) abstract number 093
- Phase 1, single-arm, open-label, dose escalation trial of microneedle array-doxorubicin in patients with mycosis fungoïdes
  (Oleg Akilov) abstract number 086

18.15 – 19.15 EORTC CLTF General Assembly and Trials Update (EORTC members only)

20.00 Congress Dinner Hotel Einstein, St.Gallen

Saturday, 29 September 2018

08.30 – 09.45 Session 8: Treatment and clinical cases
Chairs: Evangelina Papadavid, Greece
Julia Scarisbrick, UK
Pietro Quaglino, Italy
- Resminostat for Maintenance Treatment of Patients with Advanced Stage Mycosis Fungoïdes (MF) or Sézary Syndrome (SS) – a Status Update
  (Rudolf Stadler) abstract number 077
- Aggressive rare T cell lymphomas with manifestation in the skin: a monocentric cross-sectional case study
  (Marie-Charlotte Brüggen) abstract number 050
- Single-cell variability drives phenotypic heterogeneity and intrinsic drug-resistance in cutaneous T-cell lymphoma
  (Stefan Schieke) abstract number 013
- IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
  (Martine Bagot) abstract number 078
- Overcoming cell death resistance in cutaneous T cell lymphoma (CTCL) by combined Bcl-2 and NFκB inhibition
  (Jan Nicolay) abstract number 079
- Does treatment with anti-tumor necrosis factor alpha have an effect on primary cutaneous lymphoma?
  (Iris Amitay-Laish) abstract number 081
- Sézary Syndrome: A single center retrospective study with proposal for a clinical score system
  (Pietro Quaglino) abstract number 058

09.45 – 10.15 Guest lecture: Pioneering the EORTC and ISCL. From Fungus to Reticuloses and Cutaneous Lymphomas
Prof. Günter Burg, Prof. Helmut Kerl
Chairs: Emmanuella Guenova, Switzerland
Werner Kempf, Switzerland
Robert Knobler, Austria

10.15 – 10.35 Coffee/Tea break, poster and industrial exhibition
10.35 – 11.50  Session 9: Treatment and clinical cases
Chairs: Maarten Vermeer, Netherland
Rudolf Stadler, Germany

• Frequency of associated haematologic malignancies in lymphomatoid papulosis: a preliminary report of 505 patients from the Dutch Cutaneous Lymphoma Group (Rutger Melchers) abstract number 016
• Sézary syndrome, 3 injections of alemtuzumab may suffice
(Olivier Gaide) abstract number 088
• Adverse bystander effect of localized electron beam irradiation – a negative abscopal effect?
(Rose Moritz) abstract number 090
• Allogeneic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: 2018 update of the Milan experience
(Francesco Onida) abstract number 097
• Translational research with topical calcineurin inhibitors in early MF
(Lidia Maroñas-Jiménez) abstract number 099
• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
(Michael Khodadoust) abstract number 100
• Updated Combined Analysis of Two Phase II Studies of Brentuximab Vedotin in Patients with Mycosis Fungoides and Sézary Syndrome
(Auris Huen) abstract number 101

11.50 – 12.05  Poster Awards, Young Investigator Award
Emmanuella Guenova, Switzerland
Julia Scarisbrick, UK

12.15 – 13.15  Lunch Symposium
(sponsored content)

13.15 – 13.45  Session 10: Treatment and clinical cases
Chairs: Martine Bagot, France
Evangelina Papadavid, Greece

• Cytokine profile alterations in Cutaneous T-cell Lymphoma cell lines after Lenalidomide and/or Bortezomib treatment
(Vasiliki Bakou) abstract number 034
• Pediatric mycosis fungoides: management and outcomes with special focus on the folliculotropic variant
(Emmilia Hodak) abstract number 091
• Reduced Intensity allogeneic stem cell transplantation for advanced stage Mycosis Fungoides and Sézary Syndrome series of 53 patients from the UK
(Stephen Morris) abstract number 098

13.45 – 14.00  Outlook EORTC CLTF meeting 2019 and Congress Closure
Julia Scarisbrick, UK
Antonio Cozzio, Switzerland
Evangelina Papadavid, Greece

13.30 – 16.00  Swiss Patient Meeting
Kantonsspital St.Gallen
Susan Thornton, USA and CL specialists
Irving L. Weissman, MD, PhD

Irving L. Weissman is Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine; Director, Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford; Virginia & D.K. Ludwig Professor for Clinical Investigation in Cancer Research; Professor, Pathology, Developmental Biology, and, by courtesy, Biological Science and Neurosurgery at Stanford University School of Medicine. Professor Weissman received numerous awards and honors for his continuous research over the last 60 years in haematology, immunology and neurology. Among many other honors, he has been awarded with the Pasarow Award, the Robert-Koch Award, the Linus Pauling Medal, the Jessie Stevenson Kovalenko Medal, the Passano Award, the Max-Delbrück Medal, the Charles Rodolphe Brupbacher Prize, and the Karl Landsteiner Memorial Award. His interest focuses on: I. Isolation and transplantation of hematopoietic stem cells - II. Isolation of hematopoietic progenitor cells including macrophage progenitors in mouse and human – III. Understanding the clonal evolution of leukemia – IV. The discovery of CD47-SIRPa as a key modulator of programmed cell removal, and the use of this finding to develop a novel cancer immunotherapy – and V. Isolation of CNS stem cell and various solid tumor stem cells. Professor Weissman has been publishing since 1957 with currently over 800 publications of which over 80 appeared in Cell, Nature and Science.
Günter Burg, Prof. Dr. Dr. H.C.

Günter Burg was chairman of the Departments of Dermatology of the University Hospitals in Würzburg/Germany from 1988–1991 and in Zürich/Switzerland from 1991-2006, where he served as Associate Dean and Dean respectively of the University Medical School of Zürich (1998 and 2004).

Together with Helmut Kerl from Graz/Austria and some other protagonists he founded the EORTC CLTF (1980) and the International Society of Cutaneous Lymphomas (1991).

His clinical and scientific focus is on dermato-oncology and dermatopathology with special emphasis on typing and classification of cutaneous lymphomas and on treatment of melanoma. Since 1999 there is a close telemedical partnership with Nepal.

Günter Burg edited more than 30 books, including the WHO-book on Tumors of the Skin, two Lymphoma books, 2 Atlases on Dermatopathology and a book on Telemedicine.

He is Founding Editor of the webbased interactive dermatology training program DOIT (www.cyberderm.net), run by the European Dermatology Forum (EDF).

Rachael A. Clark, MD, PhD

Rachael A. Clark, the Shing-Yiu Yip and Cecilia M. Hepp Associate Professor of Dermatology at Harvard Medical School, is a physician scientist, a human immunologist, and Director of the NIH-funded Human Skin Disease Research Center. Her research focuses on the study of human T cell responses in skin and other peripheral tissues, including T cell function in healthy skin, impaired T cell migration and responses in skin cancers, and maladaptive T cell activation in inflammatory skin diseases and cutaneous lymphomas. Her studies, driven by observations in patients and carried out on human tissues, have the goals of developing novel therapies for skin disease and advancing our understanding of human immune responses.
Helmut Kerl is Professor of Dermatology and Chairman emeritus at the Department of Dermatology, Medical University of Graz, Austria. Dr. Kerl has authored over 600 scientific publications (first and senior author), several books on dermatology, and has delivered countless lectures including numerous named lectureships throughout the world. He served at the Editorial Boards of a number of prestigious dermatology and pathology journals. In 2005 he received a Lifetime Achievement Award from the International League of Dermatology. He has been elected as a Member of the German Academy of Sciences ‘Leopoldina’ (2009) and has been awarded recently the Founders Medal of the International Society of Dermatopathology. He has created a center for dermatopathology in Graz where students from all over the world come to work. His research was focused on cutaneous lymphomas, melanoma, and dermatopathology. Dr. Kerl is currently Guest Professor at the Department of Dermatology, University of Zurich, Switzerland, and Voluntary Professor of Dermatology & Cutaneous Surgery, University of Miami – Miller School of Medicine, USA.

Registration

The registration covers
• Admission to the scientific sessions
• CME European Credits 11, SGDV Credits 14, SGMO+SGH Credits 15
• Congress bag with scientific material
• Certificate of attendance
• Admission to the networking meeting
• Admission to the exhibition
• Delegate’s badge
• Coffee breaks, lunches
• Congress dinner

Services at conference site Olma Messen
• Conference information
• free internet access

Publication
Abstracts will be published as a supplement to «The European Journal of Cancer» by Elsevier.

Conference Badge
You are requested to wear your badge throughout the conference. Loss of badge means loss of registration.

Car parking
There is an underground car parking at the Olma (daily fee CHF 12.–, ticket for 3 days CHF 30.–, available at the conference desk).
Certificate of attendance/CME Credit points
Participants can obtain a certificate of attendance after the conference on the conference website on www.oncoconferences.ch.
The «EORTC-CLTF Meeting 2018» is accredited by the European Accreditation Council for Continuing Medical Education (EACCME). The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.
The «EORTC-CLTF Meeting 2018» is designated for a maximum of 11 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Programme of The Royal College of Physicians and Surgeons of Canada.
The «EORTC-CLTF Meeting 2018» is designated for a maximum of 14 hours of SGDV and 15 hours of SGMO and SGH credits as well.

Gastronomy
A list with a selection of city restaurants of various types and price levels can be obtained from the «Bodensee tourism» desk in the industry exhibition.

Local transportation
St. Gallen offers an excellent public transportation system (see map, page 23) with the railway station as central change stop. Bus No. 3 travels between the Central Railway station and «Olma» (direction «Heiligkreuz») every 7 min. Ask for your free transportation ticket at your Hotel reception desk!
There are always taxis available from the railway station to Olma Messen (approx. CHF 15.–). If you need a taxi please call +41 71 22 22 111 or +41 71 333 33 33 or contact our conference desk at the venue.

Non-smoking policy
Participants, exhibitors and exhibition visitors are kindly asked to respect the non-smoking policy.

Internet access
Olma Messen offers free WLAN. Choose the network «Free_Olma_Messen». Open your internet browser, which will lead you automatically to the registration website www.p wlan.ch. Please select the option «Free SMS Login» and enter your mobile number. A code will be sent to your mobile allowing you to enter the network.
The poster exhibition is located in hall 9.2 in front of the auditorium.

<table>
<thead>
<tr>
<th>abstract no.</th>
<th>title</th>
</tr>
</thead>
<tbody>
<tr>
<td>005</td>
<td>Identifying intratumor heterogeneity in mycosis fungoides using high throughput DNA sequencing</td>
</tr>
<tr>
<td>006</td>
<td>Using target capture based high throughput DNA sequencing methodology to identify T-cell receptor sequences in mycosis fungoides</td>
</tr>
<tr>
<td>007</td>
<td>Differential expression of TOX in hypopigmented and classical mycosis fungoides</td>
</tr>
<tr>
<td>009</td>
<td>Clonal diversity of mycosis fungoides, a mature T-cell lymphoma</td>
</tr>
<tr>
<td>011</td>
<td>T-cell repertoire next generation sequencing of skin and blood in patients with mycosis fungoides</td>
</tr>
<tr>
<td>012</td>
<td>Expression of TIGIT, BTLA, LAG3, FCRL3 and CTLA-4 in Sézary Syndrome</td>
</tr>
<tr>
<td>014</td>
<td>Metabolic dynamics control invasion and dissemination of cutaneous T-cell lymphoma</td>
</tr>
<tr>
<td>017</td>
<td>Upregulation of Integrin-associated protein on tumor T cells in CTCL inhibits IL-12 and Th1 immunity</td>
</tr>
<tr>
<td>018</td>
<td>HLA I shield tumor skin T lymphocytes from NK-cell-mediated elimination</td>
</tr>
<tr>
<td>023</td>
<td>TOX expression in patients with Mycosis fungoides— a potential diagnostic marker?</td>
</tr>
<tr>
<td>025</td>
<td>Selective inhibition of HDAC6 sensitizes CTCL to PI3K inhibitors</td>
</tr>
<tr>
<td>026</td>
<td>CTCL cell line cells secrete extracellular vesicles containing HERV-W-coded fusogenic syncytin-1</td>
</tr>
<tr>
<td>030</td>
<td>T-cell receptor clonality analysis with the Biomed-2 PCR as a diagnostic tool in cutaneous T-cell lymphomas</td>
</tr>
<tr>
<td>031</td>
<td>T-cell versus T-cell’: Tumour infiltrating lymphocytes in mycosis fungoides show a remarkably homogeneous exhaustion profile across a heterogeneous patient population</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>abstract no.</th>
<th>title</th>
</tr>
</thead>
<tbody>
<tr>
<td>039</td>
<td>Experimental modifications lead to an improved SNV detection in panel sequencing of a mycosis fungoides patient</td>
</tr>
<tr>
<td>046</td>
<td>Cutaneous lymphoma of small and medium CD4 positive cells: a report of three cases of a rare disease</td>
</tr>
<tr>
<td>047</td>
<td>Primary cutaneous diffuse large B cell lymphoma, not otherwise specified, germinal center type—Case report</td>
</tr>
<tr>
<td>048</td>
<td>Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type, with multiple lesions</td>
</tr>
<tr>
<td>049</td>
<td>A case of primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma</td>
</tr>
<tr>
<td>051</td>
<td>Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in a mycosis fungoides patient with central nervous system involvement</td>
</tr>
<tr>
<td>052</td>
<td>Clinical status of Mycosis fungoides in 636 Greek patients</td>
</tr>
<tr>
<td>053</td>
<td>Primary cutaneous anaplastic large cell lymphoma (pcALCL): Initial approach and long-term follow-up in 108 patients</td>
</tr>
<tr>
<td>054</td>
<td>Cutaneous T-cell Lymphoma and Paraneoplastic Syndromes: A Case Report and Literature Review</td>
</tr>
<tr>
<td>055</td>
<td>Lymphocytoma cutis arising in generalized morphea: a case report</td>
</tr>
<tr>
<td>056</td>
<td>Atypical Mycosis fungoides in a 51-year old woman with previous Hodgkin lymphoma</td>
</tr>
<tr>
<td>057</td>
<td>Primary cutaneous gamma/delta T-cell lymphoma: A Case Report.</td>
</tr>
<tr>
<td>059</td>
<td>Long-term complete remission induced by mogamulizumab in a severe Sézary patient, together with five different possible autoimmune manifestations</td>
</tr>
<tr>
<td>060</td>
<td>Primary cutaneous «indolent» epidermotropic cytotoxic T-cell lymphoma</td>
</tr>
<tr>
<td>062</td>
<td>Diagnostic approach to extranodal NK/T-cell lymphomas using a rare case of non-nasal type extranodal NK/T-cell lymphoma with gd-T-cell phenotype</td>
</tr>
<tr>
<td>abstract no.</td>
<td>title</td>
</tr>
<tr>
<td>-------------</td>
<td>-------</td>
</tr>
<tr>
<td>063</td>
<td>Angioimmunoblastic-T-Cell-Lymphoma mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome</td>
</tr>
<tr>
<td>064</td>
<td>Granulomatous Mycosis Fungoides, with features of Granulomatous Slack Skin. Co-morbidity with several visceral cancers, indolent course of the skin disease. Disparity of clinical picture and histopathology</td>
</tr>
<tr>
<td>065</td>
<td>Indolent hematodermic CD4+ T-cell lymphoma lacking surface CD3 expression: Structural and functional deficiency of T-cell receptor/CD3 complex</td>
</tr>
<tr>
<td>066</td>
<td>Long-term remission of relapsed subcutaneous panniculitis-like T-cell lymphoma with cyclosporine A: a case report</td>
</tr>
<tr>
<td>067</td>
<td>Primary cutaneous CD8+ CD30+ lymphoproliferative disorder in a patient with acquired CD4 immunodeficiency</td>
</tr>
<tr>
<td>068</td>
<td>ALK-positive large B-cell lymphoma – report of the first primary cutaneous case</td>
</tr>
<tr>
<td>069</td>
<td>An iatrogenic EBV-positive Cutaneous Anaplastic Large Cell Lymphoma with BRAF V600E Mutations</td>
</tr>
<tr>
<td>070</td>
<td>Not everything that looks like a bruise, is a bruise</td>
</tr>
<tr>
<td>071</td>
<td>Anaplastic large cell lymphoma in an organ transplant recipient</td>
</tr>
<tr>
<td>072</td>
<td>The use of PET-CT in detecting histologically confirmed lymphomatous nodes in cutaneous T-cell lymphoma (CTCL): A cohort study from a Tertiary Skin Lymphoma Service</td>
</tr>
<tr>
<td>073</td>
<td>Primary cutaneous marginal zone lymphoma with unusual clinical characteristics: large cell transformation and associations with DLBCL and AITL</td>
</tr>
<tr>
<td>074</td>
<td>Spongiotic mycosis fungoides: Several cases of a rare variant of cutaneous T cell lymphoma</td>
</tr>
<tr>
<td>075</td>
<td>Mortality in mycosis fungoides: Evaluation of prognostic markers and models in 58 patients</td>
</tr>
<tr>
<td>076</td>
<td>Cost of early-stage mycosis fungoides treatments in Spain</td>
</tr>
<tr>
<td>083</td>
<td>Results of helical tomotherapy on mycosis fungoides lesions</td>
</tr>
<tr>
<td>084</td>
<td>Mycosis fungoides, Insights in the latest therapy options and the possibility of a promising use of Helical tomotherapy</td>
</tr>
<tr>
<td>087</td>
<td>Risk factors for surgical site infections are different in patients with cutaneous T cell lymphoma and melanoma</td>
</tr>
<tr>
<td>089</td>
<td>Clinical experience with multimodality therapy and extracorporeal photopheresis in patients with cutaneous T-cell lymphoma, retrospective descriptive study in the Italian Hospital of Buenos Aires</td>
</tr>
<tr>
<td>095</td>
<td>Survival rates and hematological parameters of Sézary Syndrome treated with chlorambucil or interferon: an acceptable alternative when photopheresis is not available?</td>
</tr>
<tr>
<td>096</td>
<td>Different outcomes for two male patients with Sézary syndrome</td>
</tr>
<tr>
<td>102</td>
<td>A Retrospective Analysis of Clinicopathologic Features and Treatment Response Rates in Patients with Folliculotropic Mycosis Fungoides in a Series of 29 Cases</td>
</tr>
<tr>
<td>109</td>
<td>The experience of patients with cutaneous T-cell lymphoma who have undergone an allogeneic stem cell transplant: a phenomenological study</td>
</tr>
</tbody>
</table>
Satellite Symposium at the EORTC CLTF 2018
Meeting Cutaneous Lymphoma
27 September 2018, 12.45–13.45 (Lunch provided)
Hall 9.2, Olma Messen, St Gallen, Switzerland

Title: Expanding the options in MF–CTCL: changing the present, shaping the future
Chair: Julia J. Scarisbrick (UK)
Faculty: Emmanuella Guenova (Switzerland)
University Hospital Zurich, University of Zurich, Zurich, Switzerland
Julia J. Scarisbrick (UK)
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Programme

12.45–12.50 Welcome
Julia J. Scarisbrick (UK)

12.50–13.00 Introduction: an update on alkylating agents in the treatment of MF–CTCL
Emmanuella Guenova (Switzerland)

13.00–13.20 From evaluation to revolution: treatment options for MF–CTCL
Emmanuella Guenova (Switzerland)

13.20–13.40 Topical chlormethine gel: new avenues towards MF–CTCL treatment
Julia J. Scarisbrick (UK)

13.40–13.45 Close
Julia J. Scarisbrick (UK) & Emmanuella Guenova (Switzerland)

Programme Breakfast Symposium Miragen
28 September 2018, 08.00–09.00 (Breakfast provided)
Hall 9.2, Olma Messen, St Gallen, Switzerland

Topic: Presentation of Preliminary Scientific Data
Speaker: Francine Foss, MD (Professor of Medicine – Yale University)

Topic: Cobomarsen Experience in CTCL and ATLL
Speaker: Francine Foss, MD (Yale University)

Topic: SOLAR Phase 2 Cobomarsen Clinical Trial
Speakers: Diana Escolar, MD, FAAN (Senior Vice President, Clinical Science – miRagen Therapeutics)
Adam James, MPH (Associate Director, Clinical Operations – miRagen Therapeutics)
Programme Lunch Symposium Therakos / Mallinckrodt

28 September 2018, 12.45–13.45 (Lunch provided)
Hall 9.2, Olma Messen, St Gallen, Switzerland

Programme Lunch Symposium Takeda

29 September 2018, 12.15–13.15 (Lunch provided)
Hall 9.2, Olma Messen, St Gallen, Switzerland

Agenda

Date: Saturday 29 September 2018
Time: 12.15–13.15
Location: Hall 9.2, Olma Messen, St Jakob-Strasse 94, St Gallen, Switzerland

12.15–12.20  Welcome and introductions
Maarten Vermeer, Chair
Leiden University Medical Center, Leiden, The Netherlands

12.20–12.25  Challenges encountered in treating cutaneous T-cell lymphoma
José Antonio Sanches
University of São Paulo Medical School, São Paulo, Brazil

12.25–12.35  Case 1: Treatment-resistant primary cutaneous relapsed ALK-negative anaplastic large-cell lymphoma
José Antonio Sanches
University of São Paulo Medical School, São Paulo, Brazil

12.35–12.45  Case 2: An unexpected complication in a child with eczema
Maarten Vermeer

12.45–12.55  Case 3: Large-cell transformed mycosis fungoides with negative prognostic factors
Antonio Cozzio
Cantonal Hospital St Gallen, St Gallen, Switzerland

12.55–13.05  Audience Q&A/Discussion
All

13.05–13.15  How do we meet treatment challenges today and in the future?
Maarten Vermeer

All content for the satellite symposium was independently developed by the speakers. The views expressed by the speakers do not necessarily reflect the views or positions of Takeda Oncology. All trademarks are the property of their respective owners. ©2018 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved. OMS/ONC/18/0117a Date of preparation: August 2018
Contact

Kantonsspital St.Gallen
Klinik für Dermatologie, Venerologie und Allergologie
Haus 20
Rorschacher Strasse 95
CH-9007 St.Gallen

Tel. +41 71 494 19 95
dermatologie@kssg.ch
www.kssg.ch/dermatologie